RT Journal Article SR Electronic T1 Protection against reinfection with SARS-CoV-2 omicron BA.2.75* sublineage JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.10.29.22281606 DO 10.1101/2022.10.29.22281606 A1 Chemaitelly, Hiam A1 Tang, Patrick A1 Coyle, Peter A1 Yassine, Hadi M. A1 Al-Khatib, Hebah A. A1 Smatti, Maria K. A1 Hasan, Mohammad R. A1 Ayoub, Houssein H. A1 Altarawneh, Heba N. A1 Al-Kanaani, Zaina A1 Al-Kuwari, Einas A1 Jeremijenko, Andrew A1 Kaleeckal, Anvar H. A1 Latif, Ali N. A1 Shaik, Riyazuddin M. A1 Abdul-Rahim, Hanan F. A1 Nasrallah, Gheyath K. A1 Al-Kuwari, Mohamed G. A1 Butt, Adeel A. A1 Al-Romaihi, Hamad E. A1 Al-Thani, Mohamed H. A1 Al-Khal, Abdullatif A1 Bertollini, Roberto A1 Abu-Raddad, Laith J. YR 2022 UL http://medrxiv.org/content/early/2022/10/30/2022.10.29.22281606.abstract AB Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. Statements made herein are solely the responsibility of the authors. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards at Hamad Medical Corporation and Weill Cornell Medicine in Qatar approved this retrospective study with a waiver of informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.